SAN FRANCISCO, Nov. 5 – Applied Gene Technologies has entered a development, manufacturing, and marketing deal with Taiwanese biopharmaceutical company AsiaGen, the companies announced Monday.

Applied Gene Technologies, based in San Diego, will develop tuberculosis diagnostics using its Tessera Array Technology for AsiaGen, which received exclusive rights to manufacture and market the product in Asia.

Applied Gene Technologies will receive an upfront payment for the development work, according to the company. Details of the payment were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.